 JNJs acquisition of Abiomed increases the prospects of the company advancing innovation in both Medtech and the pharmaceutical business. Sales of JNJs pharmaceuticals were highest in the nine months leading to October 2, 2022, at 39.4 billion while consumer health was least at 11.1 billion, a decline of 1.1. 